|
With the help of our partners and Cummings, LLC, NSIV's 5000 square foot construction project with 600 square feet of dedicated condo space has been completed. Stay tuned for the date of the ribbon-cutting event.
|
|
Chris Ilsley (right), NSIV President & CEO, receives the keys from
Justin D'Aveta, Cummings Leasing/Property Manager.
|
|
COVID-19 Update
NSIV is requiring all member companies to have a written COVID policy for their employees, and to have that policy approved by NSIV. For those companies that have employees that are not vaccinated, Member companies must report the percentage of employees fully vaccinated to NSIV. If the number is below 100%, Member companies must also report to NSIV the test status of all unvaccinated employees within 8 hours of receiving the test results from employees.
|
|
|
At age 27, David Hysong, the President and CEO of SHEPHERD Therapeutics, was diagnosed with Adenoid Cystic Carcinoma (ACC)—an ultra-rare, untreatable head and neck cancer. David’s form of cancer, like so many others, did not respond to chemotherapy and had no approved targeted therapies. He founded Shepherd to discover, develop, and connect lifesaving cures for rare cancer patients. Shepherd pursues its drug development in a platform-agnostic manner, letting biology drive how it targets specific rare cancers using state-of-the-art technology.
|
|
|
Megan O'Connor, CEO and CoFounder of Nth Cycle, was a guest on TechCrunch's Found in a segment that was entitled "How one founder aims to help ensure you can keep upgrading your smartphone regularly." Read the whole segment here.
|
|
|
 Radical Plastics will be a partner in a new plastics biodegradation laboratory at UMass Dartmouth. The lab funded by the Commonwealth of Massachusetts will enable efficient testing of plastic biodegradation, helping address the significant waste caused by traditional plastics used in textiles, packaging, and other products that accumulate in the ocean and other water resources. Read the full press release here.
|
|
Life Science Consortium of the North Shore (LSCNS) was awarded one of Cell Signaling Technology's Education in Science (EIS) grants for 10K. Cell Signaling Technology, Inc. (CST) is a global discovery technology company and leading provider of antibodies, kits, and services, headquartered in Danvers, MA. These grants are awarded annually to support STEM educational efforts in local North Shore communities. EIS grants are a part of CST’s overall charitable programs that are designed to inspire the next generation of scientists, making it critical to the future of sustained scientific discovery.
|
|
ACTION Innovation Network is pleased to sponsor and invite you to join us at Venture Summit \ Virtual Connect
Special offer: Register Now & Save $100 off (Use discount code “ACTVIP")
Startups \ Investors \ Matchmaking
Venture Summit
Virtual Connect
December 7th - 9th 2021
Apply to Present / Nominate a company:
For more information or to be considered for one of the Top Innovator slots click here
|
|
|
MassBio announced a relaunch of its mentorship program. Now called MassBioDrive, this enhanced program is a component of MassBio's Innovation Services programming and is designed to provide early-stage entrepreneurs and academics a more robust set of resources, tools, and networks earlier in their growth trajectory to fully realize the potential of their science. Learn more about MassBio's Innovation Services programming or reach out to Massbio at drive@massbio.org.
|
|
|
|
|
